1911 related articles for article (PubMed ID: 28978710)
21. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
22. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
23. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
[TBL] [Abstract][Full Text] [Related]
24. Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses.
Nuñez IA; Ross TM
Vaccine; 2020 Jan; 38(4):830-839. PubMed ID: 31733946
[TBL] [Abstract][Full Text] [Related]
25. Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens.
Sautto GA; Kirchenbaum GA; Ecker JW; Bebin-Blackwell AG; Pierce SR; Ross TM
Immunohorizons; 2018 Aug; 2(7):226-237. PubMed ID: 31022693
[TBL] [Abstract][Full Text] [Related]
26. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
Smith G; Liu Y; Flyer D; Massare MJ; Zhou B; Patel N; Ellingsworth L; Lewis M; Cummings JF; Glenn G
Vaccine; 2017 Sep; 35(40):5366-5372. PubMed ID: 28844407
[TBL] [Abstract][Full Text] [Related]
27. A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.
Ross TM; DiNapoli J; Giel-Moloney M; Bloom CE; Bertran K; Balzli C; Strugnell T; Sá E Silva M; Mebatsion T; Bublot M; Swayne DE; Kleanthous H
Vaccine; 2019 Apr; 37(17):2369-2376. PubMed ID: 30905528
[TBL] [Abstract][Full Text] [Related]
28. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
29. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
Zost SJ; Parkhouse K; Gumina ME; Kim K; Diaz Perez S; Wilson PC; Treanor JJ; Sant AJ; Cobey S; Hensley SE
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12578-12583. PubMed ID: 29109276
[TBL] [Abstract][Full Text] [Related]
30. Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines.
Sanchez PL; Staats HF; Abraham SN; Ross TM
Sci Rep; 2024 Jun; 14(1):13800. PubMed ID: 38877101
[TBL] [Abstract][Full Text] [Related]
31. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
[TBL] [Abstract][Full Text] [Related]
32. mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020.
Allen JD; Ross TM
Front Immunol; 2024; 15():1334670. PubMed ID: 38533508
[TBL] [Abstract][Full Text] [Related]
33. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
34. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
35. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
37. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
38. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Pre-Pandemic Trivalent COBRA HA Vaccine in Mice Pre-Immune to Historical H1N1 and H3N2 Influenza Viruses.
Ge P; Ross TM
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680243
[TBL] [Abstract][Full Text] [Related]
40. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
